Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17024452 | 0.89 | LMNA (0.53) | ALDH1A1KDM4ELMNACYP2C19MAPT | |
| SCHEMBL4844769 | 0.85 | KDM4E (0.53) | HSD17B10ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL30737444 | 0.84 | LMNA (0.50) | ALDH1A1LMNACYP2C19MAPTPSEN1 | |
| SCHEMBL4833474 | 0.84 | ALDH1A1 (0.53) | HSD17B10ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL14720986 | 0.84 | MAPT (0.43) | HSD17B10ALDH1A1KDM4ELMNACYP2C19 | |
| SCHEMBL7385040 | 0.83 | GAA (0.62) | ALDH1A1LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL2909364 | 0.83 | HSD17B10 (0.59) | HSD17B10ALDH1A1KDM4ELMNAGRM4 | |
| SCHEMBL6214305 | 0.82 | PPARA (0.46) | LMNACYP2C19MAPTPSEN1PSEN2 | |
| SCHEMBL14501385 | 0.82 | PSEN1 (0.45) | ALDH1A1KDM4ELMNACYP2C19MAPT | |
| SCHEMBL14528598 | 0.82 | HSD17B10 (0.52) | HSD17B10ALDH1A1KDM4ELMNAGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7459454-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459454-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1013639-B1 | Aryl carboxylic acid and tetrazole derivatives comprising a carbamoyloxy unit | HOFFMANN LA ROCHE (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6335459-B1 | PROSTAGLANDIN I2 RECEPTOR MODULATORS; TREATING TISSUE NECROSIS, PREMATURE UTERINE CONTRACTION, GASTRIC ULCERATION, SEXUAL DYSFUNCTION, MENSTRUAL PAIN AND IMPROPER WOUND HEALING, IMMUNOREGULATION, PLATELET AGGREGATION OR NEUTROPHIL FUNCTION | SYNTEX (U.S.A.) LLC | 2002-01-01 | — | — | US | disclosed |
| EP-1013639-A1 | Aryl carboxylic acid and tetrazole derivatives comprising a carbamoyloxy unit | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062307-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | HSD17B10 4451/4885ALDH1A1 3409/4885KDM4E 1345/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | HSD17B10 4316/4885ALDH1A1 4626/4885KDM4E 4163/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | HSD17B10 4048/4885ALDH1A1 3146/4885KDM4E 480/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | HSD17B10 3966/4885ALDH1A1 4385/4885KDM4E 4463/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | HSD17B10 864/4885ALDH1A1 1676/4885KDM4E 129/4885 |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | HSD17B10 3305/4885ALDH1A1 4054/4885KDM4E 261/4885 |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | HSD17B10 4451/4885ALDH1A1 3409/4885KDM4E 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.